OVERVIEW

ASCO Highlights: Targeted Treatments for Advanced NSCLC is organized by Med-IQ.

Initial Release Date: August 15, 2024
Expiration Date: February 14, 2025

Description:
This accredited CME activity provides a comprehensive overview of novel and emerging treatments for patients with non–small cell lung carcinoma via updates from the 2024 American Society of Clinical Oncology Annual Meeting. This activity will support oncologists and the oncology care team and provide them with convenient and accessible updates on the latest clinical trial data and emerging treatments for quicker integration into patient care.

Learning Objectives:
Upon completion, participants should be able to:

  • Describe the latest targeted treatments in clinical trials for the management of advanced NSCLC
  • Integrate recently released clinical trial data on targeted treatment of advanced NSCLC into management schemes for patients who are most likely to benefit
Credits

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the learner to earn credit toward the CME requirement of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Advanced practice providers and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium/Method of Participation
This CME activity consists of a 0.5-credit #MedX. To receive credit, read the introductory CME material, read the #MedX activity, and complete the post-survey, evaluation and attestation.

  • 0.5 AMA PRA Category 1 Credit™
  • TARGET AUDIENCE

    PhysicianPhysician AssistantOncologistsHealthcare ProfessionalsNursesNurse PractitionersAdvanced Practice Providers

    SPECIALITIES

    Oncology

    RELATED ONLINE COURSES